Real-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with hepatitis C virus genotype 1 and 4.

doi:10.1111/jgh.14936

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Real-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with hepatitis C virus genotype 1 and 4.

Journal of gastroenterology and hepatology - 1 Jul 2020

Zarębska-Michaluk Dorota, Jaroszewicz Jerzy, Buczyńska Iwona, Simon Krzysztof, Lorenc Beata, Tudrujek-Zdunek Magdalena, Tomasiewicz Krzysztof, Sitko Marek, Garlicki Aleksander, Janczewska Ewa, Dybowska Dorota, Halota Waldemar, Pawłowska Małgorzata, Pabjan Paweł, Mazur Włodzimierz, Czauż-Andrzejuk Agnieszka, Berak Hanna, Horban Andrzej, Socha Łukasz, Klapaczyński Jakub, Piekarska Anna, Blaszkowska Maria, Belica-Wdowik Teresa, Dobracka Beata, Tronina Olga, Deroń Zbigniew, Białkowska-Warzecha Jolanta, Laurans Łukasz, Flisiak Robert

Abstract excerpt

BACKGROUND AND AIM: Grazoprevir/elbasvir (GZR/EBR) was approved for the treatment of chronic hepatitis C virus (HCV) genotype 1 and 4 infected patients with or without compensated liver cirrhosis. The aim of this study was to assess GZR/EBR regimen in the real-world experience, particularly in previously "difficult-to-treat" patients with chronic kidney diseases, human immunodeficiency virus-coinfected,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amides

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Benzofurans

Share to Carbamates

Share to Cyclopropanes

Share to Data Analysis

Share to Quinoxalines

Share to Renal Insufficiency, Chronic

Share to Sustained Virologic Response

Source

Open in PubMed

Identifiers

PMID: 31734959
DOI: 10.1111/jgh.14936

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with hepatitis C virus genotype 1 and 4.PMID 31734959Read ↗

Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4.Semantic proximity Read ↗

Grazoprevir/Elbasvir Treatment in Liver or Kidney Transplant Recipients with Genotype 1b Hepatitis C Virus Infection.Semantic proximity Read ↗

Elbasvir/grazoprevir is effective and tolerable for the treatment of HCV GT1-infected patients: A real world multicenter observatory study in Taiwan.Semantic proximity Read ↗

Safety and efficacy of elbasvir and grazoprevir for treatment of hepatitis C.Semantic proximity Read ↗

Effectiveness and safety of elbasvir/grazoprevir in Korean patients with hepatitis C virus infection: a nationwide real-world study.Semantic proximity Read ↗

Treating hepatitis C infection in patients with advanced CKD in the real world: time to refocus on what our real treatment goals should be.Semantic proximity Read ↗

Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R).Semantic proximity Read ↗

Are There Still Difficult-to-Treat Patients with Chronic Hepatitis C in the Era of Direct-Acting Antivirals?Semantic proximity Read ↗

Real-world effectiveness of elbasvir/grazoprevir In HCV-infected patients in the US veterans affairs healthcare system.Semantic proximity Read ↗

Effectiveness of Elbasvir/Grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population.Semantic proximity Read ↗

Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial.Semantic proximity Read ↗

[First experience with elbasvir/grazoprevir fixed-dose combination in real-life practice in the Czech Republic].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.